

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Development of vaccines for SARS-CoV-2 | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-991/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-991" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Development of vaccines for SARS-CoV-2" />
    
            <meta name="og:title" content="F1000Research Article: Development of vaccines for SARS-CoV-2.">
            <meta name="og:description" content="Read the latest article version by Wern Hann Ng, Xiang Liu, Suresh Mahalingam, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="28692">
            <meta name="article-id" content="25998">
            <meta name="dc.title" content="Development of vaccines for SARS-CoV-2">
            <meta name="dc.description" content="COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches.">
            <meta name="dc.subject" content="COVID-19, Vaccines, SARS-CoV-2">
            <meta name="dc.creator" content="Ng, Wern Hann">
            <meta name="dc.creator" content="Liu, Xiang">
            <meta name="dc.creator" content="Mahalingam, Suresh">
            <meta name="dc.date" content="2020/08/17">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.25998.1">
            <meta name="dc.source" content="F1000Research 2020 9:991">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="COVID-19">
            <meta name="prism.keyword" content="Vaccines">
            <meta name="prism.keyword" content="SARS-CoV-2">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/08/17">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="991">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.25998.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-991">
            <meta name="citation_title" content="Development of vaccines for SARS-CoV-2">
            <meta name="citation_abstract" content="COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches.">
            <meta name="citation_description" content="COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches.">
            <meta name="citation_keywords" content="COVID-19, Vaccines, SARS-CoV-2">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Wern Hann Ng">
            <meta name="citation_author_institution" content="Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University (Gold Coast Campus), Queensland, Australia">
            <meta name="citation_author" content="Xiang Liu">
            <meta name="citation_author_institution" content="Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University (Gold Coast Campus), Queensland, Australia">
            <meta name="citation_author" content="Suresh Mahalingam">
            <meta name="citation_author_institution" content="Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University (Gold Coast Campus), Queensland, Australia">
            <meta name="citation_publication_date" content="2020/08/17">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="991">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.25998.1">
            <meta name="citation_firstpage" content="991">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-991/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-991.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=28692 /> <input type=hidden id=articleId name=articleId value=25998 /> <input type=hidden id=xmlUrl value="/articles/9-991/v1/xml"/> <input type=hidden id=xmlFileName value="-9-991-v1.xml"> <input type=hidden id=article_uuid value=7818e880-4060-4a38-83c1-19244e92957b /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Development of vaccines for SARS-CoV-2"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.25998.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.25998.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-991"
  },
  "headline": "Development of vaccines for SARS-CoV-2",
  "datePublished": "2020-08-17T13:42:36",
  "dateModified": "2020-08-17T13:42:36",
  "author": [
    {
      "@type": "Person",
      "name": "Wern Hann Ng"
    },    {
      "@type": "Person",
      "name": "Xiang Liu"
    },    {
      "@type": "Person",
      "name": "Suresh Mahalingam"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-991/v1",
            "name": "Development of vaccines for SARS-CoV-2"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Development of vaccines for SARS-CoV-2 </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=28692 data-id=25998 data-downloads="" data-views="" data-scholar="10.12688/f1000research.25998.1" data-recommended="" data-doi="10.12688/f1000research.25998.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-991/v1/pdf?article_uuid=7818e880-4060-4a38-83c1-19244e92957b" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-25998-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-25998-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-25998-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Ng WH, Liu X and Mahalingam S. Development of vaccines for SARS-CoV-2 [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):991 (<a class=new-orange href="https://doi.org/10.12688/f1000research.25998.1" target=_blank>https://doi.org/10.12688/f1000research.25998.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-25998-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=25998 id=track-article-signin-25998 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/25998?target=/articles/9-991/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=28692 /> <input name=articleId type=hidden value=25998 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Development of vaccines for SARS-CoV-2</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Wern Hann Ng,&nbsp;</span><span class="">Xiang Liu,&nbsp;</span><span class=""><a href="mailto:s.mahalingam@griffith.edu.au" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Suresh Mahalingam</span></a><a href="https://orcid.org/0000-0003-3141-8410" target=_blank id=author-orcid-2><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-2><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-3141-8410</div></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Wern Hann Ng,&nbsp;</span><span class="">Xiang Liu,&nbsp;</span><span class=""><a href="mailto:s.mahalingam@griffith.edu.au" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Suresh Mahalingam</span></a><a href="http://orcid.org/0000-0003-3141-8410" target=_blank id=mauthor-orcid-2><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-2><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-3141-8410</div></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 17 Aug 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.25998.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University (Gold Coast Campus), Queensland, Australia<br/> <p> <div class=margin-bottom> Wern Hann Ng <br/> <span>Roles: </span> Conceptualization, Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Xiang Liu <br/> <span>Roles: </span> Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Suresh Mahalingam <br/> <span>Roles: </span> Conceptualization, Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=73977-69046></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=73976-69047></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> COVID-19, Vaccines, SARS-CoV-2 </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Suresh Mahalingam (<a href="mailto:s.mahalingam@griffith.edu.au">s.mahalingam@griffith.edu.au</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Suresh Mahalingam </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> SM is the recipient of a National Health and Medical Research Council (NHMRC) Senior Research Fellowship (APP11544347). <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Ng WH <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Ng WH, Liu X and Mahalingam S. Development of vaccines for SARS-CoV-2 [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):991 (<a href="https://doi.org/10.12688/f1000research.25998.1" target=_blank>https://doi.org/10.12688/f1000research.25998.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 17 Aug 2020, <b>9</b>(Faculty Rev):991 (<a href="https://doi.org/10.12688/f1000research.25998.1" target=_blank>https://doi.org/10.12688/f1000research.25998.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 17 Aug 2020, <b>9</b>(Faculty Rev):991 (<a href="https://doi.org/10.12688/f1000research.25998.1" target=_blank>https://doi.org/10.12688/f1000research.25998.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d4015e157>Introduction</h2><p class="" id=d4015e160>The first quarter of 2020 has been plagued by the emergence of a novel coronavirus disease, COVID-19 or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 was first identified in Wuhan, China, and has since spread globally at an alarming rate, with over 200 countries and territories being infected<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. In March 2020, SARS-CoV-2 was declared a global pandemic by the World Health Organization (WHO)<sup><a href="#ref-3">3</a></sup>, and as of 18 July 2020, there are over 14 million confirmed cases with over 594,000 deaths worldwide. These figures are expected to rise (<a target=xrefwindow href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports" id=d4015e173>https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports</a>)<sup><a href="#ref-2">2</a></sup>. With the emergence of SARS-CoV-2, there are currently over 2,400 listed studies on the National Institute of Health database (<a target=xrefwindow href="https://clinicaltrials.gov/ct2/results?cond=COVID-19" id=d4015e180>https://clinicaltrials.gov/ct2/results?cond=COVID-19</a>) aimed at identifying a solution to this pandemic. The development of a much-needed vaccine against SARS-CoV-2 is of utmost importance. To date, there are more than 100 vaccine candidates being developed by industry and academic institutions using a wide range of technologies including live attenuated, viral vectored, DNA/RNA-based, protein-based, and inactivated vaccines<sup><a href="#ref-4">4</a>–<a href="#ref-6">6</a></sup>. At the time of writing, 19 vaccines are recorded as being in clinical trials (<a href="#T1">Table 1</a>)<sup><a href="#ref-4">4</a>–<a href="#ref-7">7</a></sup>. This article highlights various technologies employed in vaccine development for COVID-19, potential hurdles, and recent advances.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Vaccine platforms and their current status.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d4015e213 class=n-a></a><thead><a name=d4015e215 class=n-a></a><tr><a name=d4015e217 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d4015e219 class=n-a></a>Technology<br class=br>employed</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4015e224 class=n-a></a>Developer</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4015e227 class=n-a></a>Type of vaccine candidate</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4015e230 class=n-a></a>Current stage in<br class=br>clinical evaluation</th></tr></thead><tbody><a name=d4015e237 class=n-a></a><tr><a name=d4015e239 class=n-a></a><td align=left colspan=1 rowspan=23 valign=top><a name=d4015e241 class=n-a></a><b>Non-</b><br class=br><b>replicating</b><br class=br><b>viral vector</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e251 class=n-a></a>University of Oxford/AstraZeneca</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e254 class=n-a></a>ChAdOx1-S</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e257 class=n-a></a>Phase III</td></tr><tr><a name=d4015e261 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e263 class=n-a></a>CanSino Biologics Inc and Beijing Institute of Biotechnology</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e266 class=n-a></a>Adenovirus type 5 vector</td><td align=left colspan=1 rowspan=2 valign=top><a name=d4015e269 class=n-a></a>Phase II</td></tr><tr><a name=d4015e273 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e275 class=n-a></a>Shenzhen Geno-Immune Medical Institute</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e278 class=n-a></a>Lentivirus modification</td></tr><tr><a name=d4015e282 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e284 class=n-a></a>Gamaleya Research Institute</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e287 class=n-a></a>Adeno-based</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e290 class=n-a></a>Phase I</td></tr><tr><a name=d4015e294 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e296 class=n-a></a>GeoVax/BravoVax</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e299 class=n-a></a>Modified Vaccinia Ankara (MVA)-encoded virus-like particle (VLP)</td><td align=left colspan=1 rowspan=19 valign=top><a name=d4015e302 class=n-a></a>Pre-clinical</td></tr><tr><a name=d4015e307 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e309 class=n-a></a>Stabilitech Biopharma Ltd</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e312 class=n-a></a>Oral Ad5 S</td></tr><tr><a name=d4015e316 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e318 class=n-a></a>Janssen Pharmaceutical Companies</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e321 class=n-a></a>Ad26 (alone or witd MVA boost)</td></tr><tr><a name=d4015e325 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e327 class=n-a></a>Altimmune</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e330 class=n-a></a>Adenovirus-based NasoVAX expressing SARS-CoV-2 Spike protein</td></tr><tr><a name=d4015e334 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e336 class=n-a></a>Greffex</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e339 class=n-a></a>Ad5 S (GREVAX™ platform)</td></tr><tr><a name=d4015e343 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e345 class=n-a></a>Vaxart</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e348 class=n-a></a>Oral vaccine platform</td></tr><tr><a name=d4015e352 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e354 class=n-a></a>DZIF – German Center for Infection Research</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e357 class=n-a></a>MVA-S encoded</td></tr><tr><a name=d4015e362 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e364 class=n-a></a>IDIBAPS-Hospital Clinic, Spain</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e367 class=n-a></a>MVA-S</td></tr><tr><a name=d4015e371 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e373 class=n-a></a>Greffex</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e376 class=n-a></a>Ad5 S (GREVAX™ platform)</td></tr><tr><a name=d4015e380 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e382 class=n-a></a>Centro Nacional de Biotecnología (CNB-CSIC), Spain</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e385 class=n-a></a>MVA expressing structural proteins</td></tr><tr><a name=d4015e389 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e391 class=n-a></a>Reitdera/LEUKOCARE/Univercells</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e394 class=n-a></a>Replication defective Simian adenovirus (gRAd) encoding SARS-CoV-2 S</td></tr><tr><a name=d4015e398 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e400 class=n-a></a>Valo tderapeutics Ltd</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e403 class=n-a></a>Adenovirus-based + HLA-matched peptides</td></tr><tr><a name=d4015e407 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e409 class=n-a></a>National Center for Genetic Engineering and Biotechnology<br class=br>(BIOTEC)/GPO, Thailand</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e414 class=n-a></a>Inactivated flu-based SARS-CoV2 vaccine + adjuvant</td></tr><tr><a name=d4015e419 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e421 class=n-a></a>University of Manitoba</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e424 class=n-a></a>Dendritic cell-based vaccine</td></tr><tr><a name=d4015e428 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e430 class=n-a></a>University of Georgia/University of Iowa</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e433 class=n-a></a>Parainfluenza virus 5 (PIV5)-based vaccine expressing tde Spike protein</td></tr><tr><a name=d4015e437 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e439 class=n-a></a>Bharat Biotech/Thomas Jefferson University</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e442 class=n-a></a>Recombinant deactivated rabies virus containing S1</td></tr><tr><a name=d4015e446 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e448 class=n-a></a>Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e451 class=n-a></a>Adeno-associated virus vector (AAVCOVID)</td></tr><tr><a name=d4015e455 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e457 class=n-a></a>ImmunityBio, Inc. and NantKwest, Inc.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e460 class=n-a></a>[E1-, E2b-, E3-] hAd5-COVID19-Spike/nucleocapsid</td></tr><tr><a name=d4015e464 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e466 class=n-a></a>National Research Centre, Egypt</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e469 class=n-a></a>Influenza A H1N1 vector</td></tr><tr><a name=d4015e474 class=n-a></a><td align=left colspan=1 rowspan=19 valign=top><a name=d4015e476 class=n-a></a><b>RNA</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e480 class=n-a></a>Moderna/NIAID</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e483 class=n-a></a>Lipid nanoparticle (LNP)-encapsulated mRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e486 class=n-a></a>Phase II</td></tr><tr><a name=d4015e490 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e492 class=n-a></a>BioNTech/Fosun Pharma/Pfizer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e495 class=n-a></a>Three LNP-mRNAs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e498 class=n-a></a>Phase I/II</td></tr><tr><a name=d4015e502 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e504 class=n-a></a>CureVac</td><td align=left colspan=1 rowspan=2 valign=top><a name=d4015e507 class=n-a></a>mRNA</td><td align=left colspan=1 rowspan=3 valign=top><a name=d4015e510 class=n-a></a>Phase I</td></tr><tr><a name=d4015e514 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e516 class=n-a></a>People's Liberation Army (PLA) Academy of Military Sciences/<br class=br>Walvax Biotechnology</td></tr><tr><a name=d4015e522 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e524 class=n-a></a>Imperial College London</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e527 class=n-a></a>LNP-nCoVsaRNA</td></tr><tr><a name=d4015e531 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e533 class=n-a></a>University of Tokyo/Daiichi-Sankyo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e536 class=n-a></a>LNP-encapsulated mRNA</td><td align=left colspan=1 rowspan=14 valign=top><a name=d4015e539 class=n-a></a>Pre-clinical</td></tr><tr><a name=d4015e544 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e546 class=n-a></a>Fudan University/Shanghai JiaoTong University/RNACure<br class=br>Biopharma</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e551 class=n-a></a>LNP-encapsulated mRNA cocktail encoding VLP/receptor-binding<br class=br>domain (RBD)</td></tr><tr><a name=d4015e557 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e559 class=n-a></a>China CDC/Tongji University/Stermina</td><td align=left colspan=1 rowspan=5 valign=top><a name=d4015e562 class=n-a></a>mRNA</td></tr><tr><a name=d4015e566 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e568 class=n-a></a>Arcturus Therapeutics/Duke-NUS Medical School</td></tr><tr><a name=d4015e572 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e574 class=n-a></a>FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo</td></tr><tr><a name=d4015e578 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e580 class=n-a></a>Greenlight Biosciences</td></tr><tr><a name=d4015e584 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e586 class=n-a></a>IDIBAPS-Hospital Clinic, Spain</td></tr><tr><a name=d4015e591 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e593 class=n-a></a>BIOCAD</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e596 class=n-a></a>Liposome-encapsulated mRNA</td></tr><tr><a name=d4015e600 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e602 class=n-a></a>Centro Nacional de Biotecnología (CNB-CSIC), Spain</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e605 class=n-a></a>Replicating defective SARS-CoV-2-derived RNAs</td></tr><tr><a name=d4015e609 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e611 class=n-a></a>Translate Bio/Sanofi Pasteur</td><td align=left colspan=1 rowspan=3 valign=top><a name=d4015e614 class=n-a></a>LNP-mRNA</td></tr><tr><a name=d4015e618 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e620 class=n-a></a>CanSino Biologics/Precision NanoSystems</td></tr><tr><a name=d4015e624 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e626 class=n-a></a>Chula Vaccine Research Center/University of Pennsylvania</td></tr><tr><a name=d4015e630 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e632 class=n-a></a>RNAimmune, Inc.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e635 class=n-a></a>Several mRNA candidates</td></tr><tr><a name=d4015e640 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e642 class=n-a></a>eTheRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e645 class=n-a></a>mRNA in an intranasal delivery system</td></tr><tr><a name=d4015e649 class=n-a></a><td align=left colspan=1 rowspan=15 valign=top><a name=d4015e651 class=n-a></a><b>DNA</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e655 class=n-a></a>INOVIO Pharmaceuticals</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e658 class=n-a></a>DNA plasmid vaccine with electroporation device</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e661 class=n-a></a>Phase I/II</td></tr><tr><a name=d4015e665 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e667 class=n-a></a>Cadila Healthcare Limited</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e670 class=n-a></a>DNA plasmid vaccine</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e673 class=n-a></a>Phase I/II (not yet<br class=br>recruiting)</td></tr><tr><a name=d4015e679 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e681 class=n-a></a>Genexine Consortium</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e684 class=n-a></a>DNA vaccine (GX-19)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e687 class=n-a></a>Phase I</td></tr><tr><a name=d4015e691 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e693 class=n-a></a>Takis Biotech/Applied DNA Sciences/EvviVax</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e696 class=n-a></a>DNA</td><td align=left colspan=1 rowspan=11 valign=top><a name=d4015e699 class=n-a></a>Pre-clinical</td></tr><tr><a name=d4015e703 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e705 class=n-a></a>BioNet-Asia</td><td align=left colspan=1 rowspan=2 valign=top><a name=d4015e708 class=n-a></a>DNA vaccine</td></tr><tr><a name=d4015e713 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e715 class=n-a></a>Entos Pharmaceuticals</td></tr><tr><a name=d4015e719 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e721 class=n-a></a>Mediphage Bioceuticals/University of Waterloo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e724 class=n-a></a>msDNA vaccine</td></tr><tr><a name=d4015e728 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e730 class=n-a></a>Zydus Cadila</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e733 class=n-a></a>DNA plasmid vaccine</td></tr><tr><a name=d4015e737 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e739 class=n-a></a>Karolinska Institute/Cobra Biologics (OPENCORONA Project)</td><td align=left colspan=1 rowspan=2 valign=top><a name=d4015e742 class=n-a></a>DNA with electroporation</td></tr><tr><a name=d4015e746 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e748 class=n-a></a>Chula Vaccine Research Center</td></tr><tr><a name=d4015e752 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e754 class=n-a></a>Osaka University/AnGes/Takara Bio</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e757 class=n-a></a>DNA plasmid vaccine</td></tr><tr><a name=d4015e762 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e764 class=n-a></a>Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet, Inc.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e767 class=n-a></a>Plasmid DNA, needle-free delivery</td></tr><tr><a name=d4015e771 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e773 class=n-a></a>Symvivo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e776 class=n-a></a>bacTRL-Spike</td></tr><tr><a name=d4015e780 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e782 class=n-a></a>Scancell/University of Nottingham/ Nottingham Trent University</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e785 class=n-a></a>DNA plasmid vaccine RBD and N</td></tr><tr><a name=d4015e789 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e791 class=n-a></a>National Research Centre, Egypt</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e794 class=n-a></a>DNA plasmid vaccine S, S1, S2, RBD, and N</td><td colspan=1 rowspan=1><a name=d4015e797 class=n-a></a></td></tr><tr><a name=d4015e800 class=n-a></a><td align=left colspan=1 rowspan=10 valign=top><a name=d4015e802 class=n-a></a><b>Inactivated</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e806 class=n-a></a>Sinovac</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e809 class=n-a></a>Formaldehyde-inactivated + alum</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e812 class=n-a></a>Phase III (not yet<br class=br>recruiting)</td></tr><tr><a name=d4015e818 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e820 class=n-a></a>Beijing Institute of Biological Products/Sinopharm</td><td align=left colspan=1 rowspan=3 valign=top><a name=d4015e823 class=n-a></a>Inactivated</td><td align=left colspan=1 rowspan=2 valign=top><a name=d4015e826 class=n-a></a>Phase I/II</td></tr><tr><a name=d4015e831 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e833 class=n-a></a>Wuhan Institute of Biological Products/Sinopharm</td></tr><tr><a name=d4015e837 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e839 class=n-a></a>Institute of Medical Biology, Chinese Academy of Medical Sciences</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e842 class=n-a></a>Phase I</td></tr><tr><a name=d4015e846 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e848 class=n-a></a>Osaka University/BIKEN/NIBIOHN</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e851 class=n-a></a>Unknown</td><td align=left colspan=1 rowspan=6 valign=top><a name=d4015e854 class=n-a></a>Pre-clinical</td></tr><tr><a name=d4015e858 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e860 class=n-a></a>Sinovac/Dynavax</td><td align=left colspan=1 rowspan=2 valign=top><a name=d4015e863 class=n-a></a>Inactivated + CpG 1018</td></tr><tr><a name=d4015e867 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e869 class=n-a></a>Valneva/Dynavax</td></tr><tr><a name=d4015e873 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e875 class=n-a></a>National Research Centre, Egypt</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e878 class=n-a></a>Inactivated whole virus</td></tr><tr><a name=d4015e883 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e885 class=n-a></a>Beijing Minhai Biotechnology Co., Ltd.</td><td align=left colspan=1 rowspan=2 valign=top><a name=d4015e888 class=n-a></a>Inactivated</td></tr><tr><a name=d4015e892 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e894 class=n-a></a>Research Institute for Biological Safety Problems, Rep of Kazakhstan</td></tr><tr><a name=d4015e898 class=n-a></a><td align=left colspan=1 rowspan=3 valign=top><a name=d4015e900 class=n-a></a><b>Live</b><br class=br><b>attenuated</b><br class=br><b>virus</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e910 class=n-a></a>Codagenix/Serum Institute of India</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e913 class=n-a></a>Deoptimized live attenuated vaccines</td><td align=left colspan=1 rowspan=3 valign=top><a name=d4015e916 class=n-a></a>Pre-clinical</td></tr><tr><a name=d4015e920 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e922 class=n-a></a>Indian Immunologicals Limited/Griffith University</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e925 class=n-a></a>Codon de-optimization of live attenuated vaccine</td></tr><tr><a name=d4015e929 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e931 class=n-a></a>UMC Utrecht/Radboud University</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e934 class=n-a></a>Recombinant BCG (rBCG) technology</td></tr><tr><a name=d4015e938 class=n-a></a><td align=left colspan=1 rowspan=54 valign=top><a name=d4015e939 class=n-a></a><b>Protein</b><br class=br><b>subunit</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e946 class=n-a></a>Novavax</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e949 class=n-a></a>Full-length recombinant SARS CoV-2 glycoprotein nanoparticle<br class=br>vaccine adjuvanted with Matrix (M)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e954 class=n-a></a>Phase I/II</td></tr><tr><a name=d4015e959 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e961 class=n-a></a>Clover Biopharmaceuticals Inc./GSK/Dynavax</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e964 class=n-a></a>Native like trimeric subunit Spike protein vaccine</td><td align=left colspan=1 rowspan=3 valign=top><a name=d4015e967 class=n-a></a>Phase I</td></tr><tr><a name=d4015e971 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e973 class=n-a></a>Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology,<br class=br>Chinese Academy of Sciences</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e978 class=n-a></a>Adjuvanted recombinant protein (RBD-dimer)</td></tr><tr><a name=d4015e982 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e984 class=n-a></a>Vaxine Pty Ltd/Medytox</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e987 class=n-a></a>Recombinant Spike protein with Advax™ adjuvant</td></tr><tr><a name=d4015e991 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e993 class=n-a></a>ExpreS2ion Biotechnologies</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e996 class=n-a></a>Drosophila S2 insect cell expression system VLPs</td><td align=left colspan=1 rowspan=50 valign=top><a name=d4015e999 class=n-a></a>Pre-clinical</td></tr><tr><a name=d4015e1003 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1005 class=n-a></a>Osaka University/BIKEN/National Institutes of Biomedical<br class=br>Innovation, Japan</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1010 class=n-a></a>VLP recombinant protein + adjuvant</td></tr><tr><a name=d4015e1014 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1016 class=n-a></a>Chulalongkorn University/GPO, Thailand</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1019 class=n-a></a>RBD protein fused with Fc of immunoglobulin G + adjuvant</td></tr><tr><a name=d4015e1024 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1026 class=n-a></a>AdaptVac (PREVENT-nCoV consortium)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1029 class=n-a></a>Capsid-like particle</td></tr><tr><a name=d4015e1033 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1035 class=n-a></a>Helix Biogen Consult, Ogbomoso, and Trinity Immonoefficient<br class=br>Laboratory, Ogbomoso, Oyo State, Nigeria</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1040 class=n-a></a>Subunit</td></tr><tr><a name=d4015e1044 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1046 class=n-a></a>WRAIR/USAMRIID</td><td align=left colspan=1 rowspan=3 valign=top><a name=d4015e1049 class=n-a></a>S protein</td></tr><tr><a name=d4015e1053 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1055 class=n-a></a>AJ Vaccines</td></tr><tr><a name=d4015e1059 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1061 class=n-a></a>EpiVax/University of Georgia</td></tr><tr><a name=d4015e1065 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1067 class=n-a></a>National Institute of Infectious Diseases, Japan</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1070 class=n-a></a>S protein + adjuvant</td></tr><tr><a name=d4015e1075 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1077 class=n-a></a>Sanofi Pasteur/GSK</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1080 class=n-a></a>S protein (baculovirus production)</td></tr><tr><a name=d4015e1084 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1086 class=n-a></a>University of Virginia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1089 class=n-a></a>S subunit intranasal liposomal formulation with GLA/3M052 adjuvants</td></tr><tr><a name=d4015e1093 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1095 class=n-a></a>ImmunoPrecise/LiteVax BV</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1098 class=n-a></a>Spike-based (epitope screening)</td></tr><tr><a name=d4015e1102 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1104 class=n-a></a>Vaxil Bio</td><td align=left colspan=1 rowspan=2 valign=top><a name=d4015e1107 class=n-a></a>Peptide</td></tr><tr><a name=d4015e1111 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1113 class=n-a></a>Flow Pharma Inc</td></tr><tr><a name=d4015e1117 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1119 class=n-a></a>IMV Inc</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1122 class=n-a></a>Peptide antigens formulated in lipid nanoparticle formulation</td></tr><tr><a name=d4015e1127 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1129 class=n-a></a>Generex/EpiVax</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1132 class=n-a></a>Ii-Key peptide</td></tr><tr><a name=d4015e1136 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1138 class=n-a></a>EpiVax</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1141 class=n-a></a>Protein subunit EPV-CoV-19</td></tr><tr><a name=d4015e1145 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1147 class=n-a></a>National Research Centre, Egypt</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1150 class=n-a></a>Protein subunit S, N, M and S1 protein</td></tr><tr><a name=d4015e1154 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1156 class=n-a></a>Heat Biologics/University of Miami</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1159 class=n-a></a>gp-96 backbone</td></tr><tr><a name=d4015e1163 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1165 class=n-a></a>University of Queensland/GSK/Dynavax</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1168 class=n-a></a>Molecular clamp stabilized Spike protein</td></tr><tr><a name=d4015e1172 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1174 class=n-a></a>Baylor College of Medicine</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1177 class=n-a></a>S1 or RBD protein</td></tr><tr><a name=d4015e1182 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1184 class=n-a></a>iBio/CC-Pharming</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1187 class=n-a></a>Subunit protein, plant produced</td></tr><tr><a name=d4015e1191 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1193 class=n-a></a>VIDO-InterVac, University of Saskatchewan</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1196 class=n-a></a>Adjuvanted microsphere peptide</td></tr><tr><a name=d4015e1200 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1202 class=n-a></a>LakePharma, Inc.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1205 class=n-a></a>Nanoparticle vaccine</td></tr><tr><a name=d4015e1209 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1211 class=n-a></a>Baiya Phytopharm/Chula Vaccine Research Center</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1214 class=n-a></a>Plant-based subunit<br class=br>(RBD-Fc + adjuvant)</td></tr><tr><a name=d4015e1220 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1222 class=n-a></a>Biological E Ltd</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1225 class=n-a></a>Adjuvanted protein subunit (RBD)</td></tr><tr><a name=d4015e1229 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1231 class=n-a></a>University of Saskatchewan</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1234 class=n-a></a>Adjuvanted microsphere peptide</td></tr><tr><a name=d4015e1239 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1241 class=n-a></a>University of Pittsburgh</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1244 class=n-a></a>Microneedle arrays S1 subunit</td></tr><tr><a name=d4015e1248 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1250 class=n-a></a>Saint-Petersburg Scientific Research Institute of Vaccines and<br class=br>Serums</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1255 class=n-a></a>Recombinant protein, nanoparticles (based on S-protein and other<br class=br>epitopes)</td></tr><tr><a name=d4015e1261 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1263 class=n-a></a>Innovax/Xiamen University/GSK</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1266 class=n-a></a>COVID-19 XWG-03 truncated S (Spike) proteins</td></tr><tr><a name=d4015e1270 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1272 class=n-a></a>OncoGen</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1275 class=n-a></a>Synthetic long peptide vaccine candidate for S and M proteins</td></tr><tr><a name=d4015e1279 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1281 class=n-a></a>MIGAL Galilee Research Institute</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1284 class=n-a></a>Oral <i>Escherichia coli</i>-based protein expression system of S and N proteins</td></tr><tr><a name=d4015e1291 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1293 class=n-a></a>Lomonosov Moscow State University</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1296 class=n-a></a>Structurally modified spherical particles of the tobacco mosaic virus<br class=br>(TMV)</td></tr><tr><a name=d4015e1303 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1305 class=n-a></a>University of Alberta</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1308 class=n-a></a>Spike-based</td></tr><tr><a name=d4015e1312 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1314 class=n-a></a>AnyGo Technology</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1317 class=n-a></a>Recombinant S1-Fc fusion protein</td></tr><tr><a name=d4015e1321 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1323 class=n-a></a>Yisheng Biopharma</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1326 class=n-a></a>Recombinant protein</td></tr><tr><a name=d4015e1330 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1332 class=n-a></a>Vabiotech</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1335 class=n-a></a>Recombinant S protein in IC-BEVS</td></tr><tr><a name=d4015e1339 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1341 class=n-a></a>Applied Biotechnology Institute, Inc.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1344 class=n-a></a>Orally delivered, heat-stable subunit</td></tr><tr><a name=d4015e1348 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1350 class=n-a></a>Medigen Vaccine Biologics Corporation/NIAID/Dynavax</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1353 class=n-a></a>S-2P protein + CpG 1018</td></tr><tr><a name=d4015e1358 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1360 class=n-a></a>National University of San Martin and CONICET, Argentina</td><td align=left colspan=1 rowspan=2 valign=top><a name=d4015e1363 class=n-a></a>Protein subunit</td></tr><tr><a name=d4015e1367 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1369 class=n-a></a>MOGAM Institute for Biomedical Research, GC Pharma</td></tr><tr><a name=d4015e1373 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1375 class=n-a></a>Axon Neuroscience SE</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1378 class=n-a></a>Peptides derived from Spike protein</td></tr><tr><a name=d4015e1382 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d4015e1384 class=n-a></a>Intravacc/EpiVax</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1387 class=n-a></a>Outer membrane vesicle (OMV) subunit</td></tr><tr><a name=d4015e1391 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1393 class=n-a></a>OMV peptide</td></tr><tr><a name=d4015e1397 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1399 class=n-a></a>Neovii/Tel Aviv University</td><td align=left colspan=1 rowspan=2 valign=top><a name=d4015e1402 class=n-a></a>RBD-based</td></tr><tr><a name=d4015e1407 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1409 class=n-a></a>Kentucky Bioprocessing, Inc</td></tr><tr><a name=d4015e1413 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1415 class=n-a></a>Quadram Institute</td><td align=left colspan=1 rowspan=2 valign=top><a name=d4015e1418 class=n-a></a>OMV-based vaccine</td></tr><tr><a name=d4015e1422 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1424 class=n-a></a>BiOMViS Srl/University of Trento</td></tr><tr><a name=d4015e1428 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d4015e1430 class=n-a></a>FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1433 class=n-a></a>Peptide vaccine</td></tr><tr><a name=d4015e1437 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1439 class=n-a></a>Subunit vaccine</td></tr><tr><a name=d4015e1443 class=n-a></a><td align=left colspan=1 rowspan=11 valign=top><a name=d4015e1444 class=n-a></a><b>Virus-like particles</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1448 class=n-a></a>Medicago Inc./Université Laval</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1451 class=n-a></a>Plant-derived VLP</td><td align=left colspan=1 rowspan=11 valign=top><a name=d4015e1454 class=n-a></a>Pre-clinical</td></tr><tr><a name=d4015e1459 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1461 class=n-a></a>Saiba GmbH</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1464 class=n-a></a>VLP based on RBD displayed on VLPs</td></tr><tr><a name=d4015e1468 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1470 class=n-a></a>Navarrabiomed, Oncoimmunology group</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1473 class=n-a></a>VLPs, lentivirus and baculovirus vehicles</td></tr><tr><a name=d4015e1477 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1479 class=n-a></a>VBI Vaccines Inc.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1482 class=n-a></a>Enveloped VLP (eVLP)</td></tr><tr><a name=d4015e1486 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1488 class=n-a></a>Mahidol University/The Government Pharmaceutical Organization<br class=br>(GPO)/Siriraj Hospital</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1493 class=n-a></a>VLP + adjuvant</td></tr><tr><a name=d4015e1497 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1499 class=n-a></a>IrsiCaixa AIDS Research Institute/IRTA-CReSA/Barcelona<br class=br>Supercomputing Centre/Grifols</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1504 class=n-a></a>S protein integrated in HIV VLPs</td></tr><tr><a name=d4015e1508 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1510 class=n-a></a>Imophoron Ltd and Bristol University Max Planck Centre</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1513 class=n-a></a>ADDomer™ multiepitope display</td></tr><tr><a name=d4015e1518 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1520 class=n-a></a>Doherty Institute</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1523 class=n-a></a>Unknown</td></tr><tr><a name=d4015e1527 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1529 class=n-a></a>OSIVAX</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1532 class=n-a></a>VLP</td></tr><tr><a name=d4015e1536 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1538 class=n-a></a>University of Sao Paulo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1541 class=n-a></a>VLPs/whole virus</td></tr><tr><a name=d4015e1545 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1547 class=n-a></a>ARTES Biotechnology</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1550 class=n-a></a>eVLP</td></tr><tr><a name=d4015e1554 class=n-a></a><td align=left colspan=1 rowspan=16 valign=top><a name=d4015e1555 class=n-a></a><b>Replicating</b><br class=br><b>viral vector</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1562 class=n-a></a>Shenzhen Geno-Immune Medical Institute</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1565 class=n-a></a>Minigenes engineered based on multiple viral genes, using an<br class=br>efficient lentiviral vector system (NHP/TYF) to express viral proteins<br class=br>and immune modulatory genes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1572 class=n-a></a>Phase I</td></tr><tr><a name=d4015e1576 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1578 class=n-a></a>Cadila Healthcare Limited</td><td align=left colspan=1 rowspan=3 valign=top><a name=d4015e1581 class=n-a></a>Measles vector</td><td align=left colspan=1 rowspan=15 valign=top><a name=d4015e1584 class=n-a></a>Pre-clinical</td></tr><tr><a name=d4015e1589 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1591 class=n-a></a>Institute Pasteur/Themis/University of Pittsburg Center for Vaccine<br class=br>Research</td></tr><tr><a name=d4015e1597 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1599 class=n-a></a>FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo</td></tr><tr><a name=d4015e1603 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1605 class=n-a></a>DZIF – German Center for Infection Research/CanVirex AG</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1608 class=n-a></a>Measles virus (S, N targets)</td></tr><tr><a name=d4015e1612 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1614 class=n-a></a>Tonix Pharmaceuticals/Southern Research</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1617 class=n-a></a>Horsepox vector expressing S protein</td></tr><tr><a name=d4015e1621 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1623 class=n-a></a>University of Hong Kong</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1626 class=n-a></a>Influenza vector expressing RBD</td></tr><tr><a name=d4015e1630 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1632 class=n-a></a>IAVI/Merck</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1635 class=n-a></a>Replication-competent vesicular stomatitis virus (VSV) chimeric virus<br class=br>technology (VSVΔG) delivering the SARS-CoV-2 Spike (S) glycoprotein</td></tr><tr><a name=d4015e1642 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1644 class=n-a></a>BIOCAD and IEM</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1647 class=n-a></a>Live viral vectored vaccine based on attenuated influenza virus<br class=br>backbone (intranasal)</td></tr><tr><a name=d4015e1653 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1655 class=n-a></a>Lancaster University, UK</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1658 class=n-a></a>Avian paramyxovirus vector (APMV)</td></tr><tr><a name=d4015e1662 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1664 class=n-a></a>FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1667 class=n-a></a>Recombinant vaccine based on influenza A virus for the prevention of<br class=br>COVID-19 (intranasal) VSV vector</td></tr><tr><a name=d4015e1673 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1675 class=n-a></a>University of Western Ontario</td><td align=left colspan=1 rowspan=2 valign=top><a name=d4015e1678 class=n-a></a>VSV-S</td></tr><tr><a name=d4015e1682 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1684 class=n-a></a>Israel Institute for Biological Research/Weizmann Institute of<br class=br>Science</td></tr><tr><a name=d4015e1690 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1692 class=n-a></a>Fundação Oswaldo Cruz and Instituto Butantan</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1695 class=n-a></a>Attenuated influenza expressing an antigenic portion of the Spike<br class=br>protein</td></tr><tr><a name=d4015e1702 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1704 class=n-a></a>Intravacc/Wageningen Bioveterinary Research/Utrecht University</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1707 class=n-a></a>Newcastle disease virus vector (NDV-SARS-CoV-2/Spike)</td></tr><tr><a name=d4015e1711 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1713 class=n-a></a>UW–Madison/FluGen/Bharat Biotech</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1716 class=n-a></a>M2-deficient single replication (M2SR) influenza vector</td></tr><tr><a name=d4015e1720 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1722 class=n-a></a><b>Unknown</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1726 class=n-a></a>Tulane University</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1729 class=n-a></a>Unknown</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1732 class=n-a></a>Pre-clinical</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d4015e1740 class=n-a></a><p id=d4015e1742> The table was adapted from<sup><a href="#ref-5">5</a>,<a href="#ref-6">6</a>,<a href="#ref-21">21</a></sup>.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4015e1761>DNA/RNA-based platforms</h2><p class="" id=d4015e1764>DNA- and RNA-based platforms present the greatest potential for speed of production since culturing and fermentation are not required for their synthesis. The potential of this approach is showcased by Moderna, whose vaccine candidate advanced to clinical testing just 2 months after sequence identification<sup><a href="#ref-7">7</a></sup>. There are many other advantages associated with DNA-based vaccines. Notably, they are renowned for their safety profile since the vectors employed are non-replicating and encode and express only the target antigen. The vectors therefore are unable to revert to a disease-causing form, which is a risk with viral vectors. Another key advantage with DNA-based vaccination is the absence of vector-specific immunity, which allows these products to be utilized in prime and boost regimens with multiple products intended for the same patient<sup><a href="#ref-8">8</a></sup>. RNA-based vaccines are also a promising alternative owing to their potential for low-cost manufacture and good safety profile in animal studies<sup><a href="#ref-9">9</a>–<a href="#ref-11">11</a></sup>. However, both DNA- and RNA-based vaccines have their own set of challenges. Both vaccines could suffer from the drawback of having low immunogenicity, as DNA vaccines could potentially integrate into the human genome, while there are concerns about the stability of RNA vaccines<sup><a href="#ref-12">12</a></sup>. As there are currently no approved DNA or RNA vaccines for medical use in humans<sup><a href="#ref-12">12</a>,<a href="#ref-13">13</a></sup>, the question about low immunogenicity has not yet been resolved (<a href="#T2">Table 2</a>). The lack of currently approved DNA or RNA vaccines provides considerable regulatory uncertainty, and their progression through the regulatory process will almost certainly take significantly longer than for more conventional vaccine technologies. Currently, there is one vaccine in phase II clinical trials, three in phase I/II clinical trials, and four in phase I clinical trials for SARS-CoV-2 based on the DNA/RNA platform. Inovio Pharmaceuticals is developing a SARS-CoV-2 vaccine, INO-4800, using a DNA-based platform, with phase I clinical trials being undertaken in conjunction with pre-clinical studies in order to hasten development<sup><a href="#ref-14">14</a></sup>. The International Vaccine Institute (IVI) has announced that the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded $6.9 million of funding to INOVIO to work with IVI and the Korea National Institute of Health (KNIH) for a phase I/II clinical trial of INO-4800 in South Korea. The trial will be conducted in parallel with INOVIO’s phase I study, which is currently ongoing with 40 healthy adults receiving the vaccine candidate and will eventually be expanded to older adults<sup><a href="#ref-15">15</a></sup>. An RNA vaccine candidate, mRNA-1273, is being developed by Moderna in collaboration with NIAID. The Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS), has agreed to cooperate to hasten the development of mRNA-1273 by pledging up to $483 million in funding<sup><a href="#ref-16">16</a></sup>. Healthy adults aged 18 to 55 were recruited for phase I trials. Two injections of mRNA-1273 were given 28 days apart at a dose of 25 μg, 100 μg, or 250 μg. Dire adverse events were absent, and no trial halting rules were met, although one participant in the 25 μg group withdrew because of an unsolicited adverse event, transient urticaria, which was postulated to be linked to the first vaccination. Live virus neutralization capable of reducing SARS-CoV-2 infectivity by 80% or more was detected at day 43 post-vaccination in all participants. Of the three doses evaluated, the 100 μg dose was optimal based on its capacity to trigger high neutralization responses and Th1-skewed CD4 T cell responses. The reactogenicity profile at 100 μg was better than for the other two doses. The safety, reactogenicity, and immunogenicity of mRNA-1273 are currently being evaluated in phase II trials using two vaccinations given 28 days apart. A total of 600 participants, 300 aged 18–54 and 300 aged 55 and above, have been assigned to three groups: placebo, 50 μg of vaccine, or 100 μg of vaccine at both vaccinations<sup><a href="#ref-17">17</a></sup>. A phase III trial of mRNA-1273 is expected to begin in July with an estimated 30,000 participants. With the expected final dose of 100 μg, Moderna is confident to scale up manufacturing to approximately 500 million to 1 billion doses per year<sup><a href="#ref-18">18</a></sup>.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Pros and cons of different vaccine formulations and examples of licensed vaccines.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d4015e1828 class=n-a></a><thead><a name=d4015e1830 class=n-a></a><tr><a name=d4015e1832 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d4015e1834 class=n-a></a>Vaccine platforms</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4015e1837 class=n-a></a>Pros</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4015e1840 class=n-a></a>Cons</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4015e1843 class=n-a></a>Examples of licensed vaccines<br class=br>targeted for humans</th></tr></thead><tbody><a name=d4015e1850 class=n-a></a><tr><a name=d4015e1852 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1854 class=n-a></a><b>RNA</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1858 class=n-a></a>•&nbsp;&nbsp;&nbsp;Potential low-cost<br class=br>manufacturing<br class=br>•&nbsp;&nbsp;&nbsp;Ease of manufacturing<br class=br>•&nbsp;&nbsp;&nbsp;Good safety profile</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1867 class=n-a></a>•&nbsp;&nbsp;&nbsp;May have low immunogenicity<br class=br>due to instability<br class=br>•&nbsp;&nbsp;&nbsp;May require multiple doses</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1874 class=n-a></a>-</td></tr><tr><a name=d4015e1877 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1878 class=n-a></a><b>DNA</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1882 class=n-a></a>•&nbsp;&nbsp;&nbsp;Potential low-cost<br class=br>manufacturing<br class=br>•&nbsp;&nbsp;&nbsp;Ease of manufacturing<br class=br>•&nbsp;&nbsp;&nbsp;Good safety profile<br class=br>•&nbsp;&nbsp;&nbsp;Good stability<br class=br>•&nbsp;&nbsp;&nbsp;Does not induce anti-vector<br class=br>immunity</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1898 class=n-a></a>•&nbsp;&nbsp;&nbsp;Potential integration to human<br class=br>genome<br class=br>•&nbsp;&nbsp;&nbsp;Low immunogenicity</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1905 class=n-a></a>-</td></tr><tr><a name=d4015e1908 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1909 class=n-a></a><b>Virus vectors</b><br class=br><b>(replicating/non-</b><br class=br><b>replicating viral vectors</b><br class=br><b>and virus-like particles)</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1922 class=n-a></a>•&nbsp;&nbsp;&nbsp;High-efficiency gene<br class=br>transduction<br class=br>•&nbsp;&nbsp;&nbsp;High specific delivery of genes<br class=br>to target cells<br class=br>•&nbsp;&nbsp;&nbsp;Induction of robust immune<br class=br>responses<br class=br>•&nbsp;&nbsp;&nbsp;Increased cellular immunity</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1938 class=n-a></a>•&nbsp;&nbsp;&nbsp;Low titer production<br class=br>•&nbsp;&nbsp;&nbsp;May induce anti-vector<br class=br>immunity<br class=br>•&nbsp;&nbsp;&nbsp;Generation of replication-<br class=br>competent virus, which can<br class=br>induce tumorigenesis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1951 class=n-a></a>•&nbsp;&nbsp;&nbsp;JYNNEOS (Smallpox/<br class=br>Monkeypox)<br class=br>•&nbsp;&nbsp;&nbsp;ACAM2000 (Smallpox)<br class=br>•&nbsp;&nbsp;&nbsp;Adenovirus type 4 and type 7<br class=br>vaccine, live, oral (febrile acute<br class=br>respiratory)</td></tr><tr><a name=d4015e1964 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1965 class=n-a></a><b>Inactivated</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1969 class=n-a></a>•&nbsp;&nbsp;&nbsp;Good safety profile<br class=br>•&nbsp;&nbsp;&nbsp;Can be used in<br class=br>immunocompromised patients</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1976 class=n-a></a>•&nbsp;&nbsp;&nbsp;Requires booster doses<br class=br>•&nbsp;&nbsp;&nbsp;Low production titer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1981 class=n-a></a>•&nbsp;&nbsp;&nbsp;Poliovax (Polio)<br class=br>•&nbsp;&nbsp;&nbsp;Flucelvax Quadrivalent<br class=br>(Influenza)<br class=br>•&nbsp;&nbsp;&nbsp;Ixiaro (Japanese Encephalitis)<br class=br>•&nbsp;&nbsp;&nbsp;Imovax (Rabies)</td></tr><tr><a name=d4015e1992 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1993 class=n-a></a><b>Live attenuated virus</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e1997 class=n-a></a>•&nbsp;&nbsp;&nbsp;High potency<br class=br>•&nbsp;&nbsp;&nbsp;Triggers long-lasting immunity<br class=br>•&nbsp;&nbsp;&nbsp;Low-cost manufacturing</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e2004 class=n-a></a>•&nbsp;&nbsp;&nbsp;Possible regression to virulence<br class=br>strain<br class=br>•&nbsp;&nbsp;&nbsp;Limited use in<br class=br>immunocompromised patients</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e2013 class=n-a></a>•&nbsp;&nbsp;&nbsp;ERVEBO (Ebola virus)<br class=br>•&nbsp;&nbsp;&nbsp;MMR II (Measles, Mumps, and<br class=br>Rubella)<br class=br>•&nbsp;&nbsp;&nbsp;BCG vaccine (Tuberculosis)</td></tr><tr><a name=d4015e2023 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e2024 class=n-a></a><b>Protein subunit</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e2028 class=n-a></a>•&nbsp;&nbsp;&nbsp;Can be used in<br class=br>immunocompromised patients<br class=br>•&nbsp;&nbsp;&nbsp;Good safety profile</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e2035 class=n-a></a>•&nbsp;&nbsp;&nbsp;Low immunogenicity<br class=br>•&nbsp;&nbsp;&nbsp;Conjugation could lead to<br class=br>batch-wise variation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4015e2042 class=n-a></a>•&nbsp;&nbsp;&nbsp;PedvaxHIB<br class=br>(<i>Haemophilus</i><i>influenzae</i> type b)<br class=br>•&nbsp;&nbsp;&nbsp;Engerix-B (Hepatitis B)<br class=br>•&nbsp;&nbsp;&nbsp;Recombivax HB (Hepatitis B)</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d4015e2060 class=n-a></a><p id=d4015e2062> This table was adapted from<sup><a href="#ref-8">8</a>–<a href="#ref-11">11</a>,<a href="#ref-20">20</a>,<a href="#ref-22">22</a>–<a href="#ref-28">28</a></sup>.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4015e2087>Virus vectors</h2><p class="" id=d4015e2090>Virus-based vectors are powerful tools for vaccination. Their effectiveness stems from their ability to infect cells, which allows them to be highly efficient, specific, and able to trigger robust immune responses. Despite their advantages, viral vectors have several disadvantages (<a href="#T2">Table 2</a>). For example, the use of vaccinia virus and adenovirus may lead to immunity against the vector, which will reduce the efficacy of the vaccine. The use of retrovirus and lentivirus, on the other hand, may lead to the risk of tumorigenesis in patients, which results from the integration of viral long terminal repeats into proto-oncogenes<sup><a href="#ref-19">19</a></sup>. Additionally, certain viral vectors such as adeno-associated virus may not be cost effective owing to their low titer production<sup><a href="#ref-20">20</a></sup>. Ultimately, viral vectors still present themselves as a valid choice for vaccine development against SARS-CoV-2, as illustrated by their successful use in the eradication of smallpox<sup><a href="#ref-20">20</a></sup>. Examples of such vaccines currently under development are ChAdOx1-S, Ad5-nCoV, aAPC, and LV-SMENP-DC. The latter two vaccines, developed by Shenzhen Geno-Immune Medical Institute, are currently in phase I (aAPC) and phase II (LV-SMENP-DC) clinical studies. The Ad5-nCoV vaccine pioneered by CanSino Biologics is the first SARS-CoV-2 vaccine to reach phase II clinical trials<sup><a href="#ref-5">5</a></sup>. Phase I clinical studies for Ad5-nCoV were conducted between March 16 and March 27. No serious adverse events within 28 days of vaccination were reported in vaccine recipients. Specific antibodies, including neutralizing antibodies, increased significantly at day 14 and peaked 28 days post-vaccination. Specific T-cell response peaked at day 14 post-vaccination<sup><a href="#ref-29">29</a></sup>. A phase II study is currently underway with 500 participants registered in three different groups: 250 participants will receive the vaccine, 125 participants will receive a lower vaccine dose, and 125 participants will receive placebo. The immune response will be tested at 0, 14, and 28 days and 6 months after vaccination<sup><a href="#ref-30">30</a></sup>. ChAdOx1-S, developed by the University of Oxford in partnership with AstraZeneca, is the first vaccine candidate to reach phase III clinical trials<sup><a href="#ref-1">1</a>,<a href="#ref-5">5</a></sup>. A study has reported that a single dose of the vaccine is able to elicit a strong immune response in rhesus macaques<sup><a href="#ref-31">31</a></sup>. Additionally, a trial study conducted in pigs demonstrated that ChAdOx is able to elicit a greater antibody response when given a booster shot, suggesting that a two-dose approach may give better protection in humans against SARS-CoV-2<sup><a href="#ref-32">32</a></sup>. However, it should be noted that nose swabs and oropharynx and mediastinal lymph node testing revealed viral gRNA in both vaccinated and control animal groups at 3 and 5 days post-inoculation. Interestingly, viral genome was detected in cervical lymph node in the vaccinated group but not in the control group. Detection of virus in these tissues indicates the vaccine does not provide complete protection against SARS-CoV-2 infection. Viral RNA (gRNA and sgRNA) load in lung tissue was also shown to vary dramatically between individual animals but was determined to be significantly lower in the vaccinated group than in the control group. Another troubling result to note from this study is that despite observing neutralizing antibodies in vaccinated animals, the titers reported were extremely low<sup><a href="#ref-31">31</a></sup>. Generally, neutralizing antibodies elicited by effective vaccines can be diluted more than a thousand-fold and still maintain their effectiveness<sup><a href="#ref-33">33</a></sup>. However, the results reported by Oxford show that the serum could be diluted only 4- to 40-fold before losing its neutralizing activity<sup><a href="#ref-31">31</a>,<a href="#ref-33">33</a></sup>. ChAdOx1-S was well tolerated in humans, with a trial of over 320 vaccinated individuals showing no strong adverse effects<sup><a href="#ref-34">34</a></sup>. The phase III clinical trials of this vaccine will involve 8,000 individuals in the United Kingdom, 5,000 individuals in Brazil, and 2,000 individuals in South Africa<sup><a href="#ref-35">35</a></sup>. AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA) to supply up to 400 million doses of ChAdOx1-S starting by the end of 2020 at no profit. The total manufacturing capacity of this vaccine currently stands at 2 billion doses<sup><a href="#ref-34">34</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4015e2167>Inactivated vaccines</h2><p class="" id=d4015e2170>Inactivated vaccines have been successfully employed over the past 70 years and are widely used today<sup><a href="#ref-36">36</a></sup>. Inactivated vaccines are produced using bacteria or viruses by deactivating them with heat, chemicals, or radiation. These processes terminate the pathogen’s ability to replicate, leading to them being more stable and having higher safety profiles. These attributes allow for their use in immunocompromised individuals<sup><a href="#ref-37">37</a></sup>. However, the characteristics that contribute to their strengths are also weaknesses. As the pathogens are inactivated, these vaccines generally stimulate a much weaker immune response than live vaccines and require several doses for effective immunity to be established. The immune response to an inactivated vaccine is also typically humoral. Antibody titers against the targeted antigen will diminish with time, leading to the need for booster shots<sup><a href="#ref-22">22</a>,<a href="#ref-36">36</a></sup> (<a href="#T2">Table 2</a>). Regardless, inactivated vaccines are effective agents that have prevented countless deaths due to various infections in humans, notably against wild poliovirus 2, which has not been detected since 1999 and was declared eradicated in September 2015 by WHO<sup><a href="#ref-38">38</a></sup>. There are currently nine inactivated vaccine candidates for SARS-CoV-2 listed by WHO. Of these, one vaccine candidate—PiCoVacc, developed by Sinovac—is listed as ready to commence phase III clinical trials and is in the midst of preparing to recruit participants. It is very promising to note that Sinovac Biotech has demonstrated protection by PiCoVacc against SARS-CoV-2 in monkeys. Monkeys were immunized three times with two different doses (3 or 6 μg per dose) of PiCoVacc at day 0, 7, and 14 before virus challenge at week 3. It was demonstrated that monkeys vaccinated with PiCoVacc produced anti-SARS-CoV-2 neutralizing antibody titers similar to those of recovered patients. This study also indicated that PiCoVacc is safe, as there was no infection enhancement or immunopathological exacerbation observed in vaccinated monkeys. PiCoVacc is currently in phase I human clinical trials as stated above. The company plans to initiate phase II and III clinical trials with PiCoVacc by the end of this year<sup><a href="#ref-39">39</a></sup>. There are two other inactivated vaccine candidates being developed by the Beijing Institute of Biological Products and the Wuhan Institute of Biological Products, respectively, both of which are currently in phase I/II clinical trials. Both institutes are collaborating with Sinopharm for the development of these vaccines.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4015e2203>Live attenuated virus</h2><p class="" id=d4015e2206>Another promising approach in vaccine design is the use of live attenuated virus (LAV), developed by codon deoptimization. This technology has proven itself to be cost effective for large-scale manufacturing and has a smooth regulatory approval pathway, as it has demonstrated high efficacy and potency in both <i>in vitro</i> and <i>in vivo</i> experiments against different respiratory viruses in mice, human cells, and non-human primates, providing lasting immunity with just a single dose<sup><a href="#ref-23">23</a>–<a href="#ref-25">25</a></sup>. LAV have a simple production process using well-established Vero cells, which are currently the most widely accepted cell line by regulatory authorities for vaccine development, since they have been in use for vaccine manufacturing for nearly 40 years. LAVs are also proven to grow and infect microcarrier beads in large-scale fermenters up to 6,000 L and in serum free media with zero loss in production output<sup><a href="#ref-40">40</a></sup>. Existing manufacturing infrastructure can be easily utilized because of its cost effectiveness for large-scale manufacturing<sup><a href="#ref-41">41</a></sup>. LAV has certain drawbacks, notably the existing possibility of reversion to virulence, which has strong safety implications, especially in immunocompromised patients<sup><a href="#ref-26">26</a></sup> (<a href="#T2">Table 2</a>). Nonetheless, codon deoptimization technology in vaccine design has promise against SARS-CoV-2. It is a tried and tested new engineering technology, and designs such as introducing point mutations have proved that the drawbacks can be overcome with relative ease<sup><a href="#ref-42">42</a></sup>. One example of its recent use is in a vaccine against Ebola virus, where an estimated efficacy of 97.5% was recorded from a preliminary analysis of 90,000 individuals who were exposed for 10 days or more to Ebola virus after vaccination<sup><a href="#ref-43">43</a></sup>. Codon deoptimization vaccine candidates have virtually no risk of reversion to virulence because of the large number of substitutions that are made in the coding sequence. This is a crucial safety feature of vaccines developed using codon deoptimization. Vaccines developed against SARS-CoV-2 using LAV technology are all currently in pre-clinical development. For example, Indian Immunologicals Limited is currently working together with Griffith University to develop a vaccine using codon deoptimization as a strategy against SARS-CoV-2. The vaccine candidate is expected to provide a long-lasting immunity against SARS-CoV-2 following a single vaccination and is also expected to provide cross-protection against other coronaviruses such as MERS and SARS-CoV-1<sup><a href="#ref-44">44</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4015e2254>Protein subunit</h2><p class="" id=d4015e2257>Protein subunit vaccines are a popular choice for the design of a SARS-CoV-2 vaccine owing to their strong safety profile, which is particularly advantageous for immunocompromised patients. They are less likely to cause complications in vaccinated individuals, as the antigenic components employed in protein subunit vaccines are purified and do not involve the use of infectious viruses<sup><a href="#ref-45">45</a></sup>. However, as with other vaccine platforms, protein subunit vaccines come with their own set of challenges, with the most prominent one being their lack of efficacy. A subunit vaccine presents an antigen to the immune system without the involvement of viral particles using a specific, isolated protein of the pathogen. In the likely scenario where the isolated proteins are denatured, they will become associated with other antibodies different from what was initially targeted, leading to the lack of efficacy<sup><a href="#ref-46">46</a></sup> (<a href="#T2">Table 2</a>). Nonetheless, novel designs and delivery can overcome this limitation and demonstrate enhanced efficacy, e.g. against Zika virus in animal studies and against malaria in <i>in vivo</i> studies<sup><a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup>. The success of protein subunit vaccines is highlighted by the hepatitis B vaccine, and we have now controlled these diseases to the point of virtual elimination<sup><a href="#ref-49">49</a>,<a href="#ref-50">50</a></sup>. Currently, there are many vaccines under pre-clinical studies using this platform. For example, Danish company Expression Biotechnologies has announced that it was awarded an EU horizon 2020 grant amounting to €2.7 million for the development of a SARS-CoV-2 vaccine candidate. The company aims to conduct phase I/IIa clinical trials within 12 months after preliminary studies<sup><a href="#ref-51">51</a></sup>. One other notable example of a vaccine candidate designed on the basis of this platform is developed by Novavax, which is currently in phase I/II clinical trials. There are three other protein subunit vaccine candidates currently in phase I clinical trials<sup><a href="#ref-5">5</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4015e2300>Outlook</h2><p class="" id=d4015e2303>SARS-CoV-2 has given rise to an unprecedented economic, health, and societal challenge globally. The key to tackle this pandemic is the development of safe and effective vaccines. Monumental energy has been poured into vaccine R&amp;D; however, there are many challenges that need to be overcome before a successful marketable vaccine becomes available. Over 100 vaccine candidates are in pre-clinical trials, with 19 in clinical trials and many others in early development<sup><a href="#ref-5">5</a>,<a href="#ref-6">6</a></sup>. Vaccine developers are turning a blind eye to industrial benchmarks for traditional vaccine development, as speed is considered a major priority in developing a successful vaccine against SARS-CoV-2. For example, clinical trials are being conducted simultaneously instead of sequentially using adaptive designs that are optimized for speed. Researchers, manufacturers, funders, and governing parties are targeting vaccines to be available by 2021, impelling proposals to move forward with reduced numbers of study participants and cut short safety follow-up in clinical studies. A successful COVID-19 vaccine will be administered on a global scale; thus, its safety profile must be solid. Therefore, approaches for generating a COVID-19 vaccine must not compromise safety aspects and will require careful evaluation of effectiveness and safety at each step to avoid major setbacks. There are also unresolved obstacles in ensuring global access to a developed COVID-19 vaccine. For example, during the early days of the HIV and H1N1 outbreaks, even after the successful development of a vaccine, it was difficult to achieve global distribution. Similarly, for COVID-19, a vaccine approved for marketing does not necessarily lead to easy accessibility. Manufacturing capability must be enhanced so that the production of vaccine doses can be magnified while ensuring vaccine affordability for the global community. Coordinated efforts among vaccine developers, funders, and manufacturers are essential to ensure that successful vaccine candidates can be manufactured in adequate numbers and distributed evenly across the globe.</p><p class="" id=d4015e2313>Another important issue is whether COVID-19 vaccines will sensitize humans to a phenomenon known as antibody-dependent enhancement (ADE). Although antibodies are generally protective, rare cases have been documented in which pathogen-specific antibodies enhance disease—a phenomenon known as ADE. ADE is most prominently associated with dengue virus<sup><a href="#ref-52">52</a></sup>. ADE has also been observed for both MERS and SARS-CoV-1 despite evidence pointing towards the fact that coronavirus diseases in humans lack the clinical, epidemiological, biological, or pathological attributes of ADE exemplified by the dengue viruses. Therefore, ADE warrants full consideration in the safety profiling of potential vaccine candidates against SARS-CoV-2 to avoid this phenomenon being observed, as SARS-CoV-2 shares a high sequence identity with SARS-CoV-1<sup><a href="#ref-53">53</a>,<a href="#ref-54">54</a></sup>.</p><p class="" id=d4015e2327>Safety aspects of the COVID-19 vaccines under development are of the utmost importance. Thorough clinical trials need to be carried out prior to marketing of the vaccine. Recent reports in India on the possibility of launching a vaccine in record time without allowing sufficient time for clinical trials are disturbing. Although COVID-19 vaccine development is of the utmost global importance, it is crucial that we do not cut corners and that vaccines are approved only after having passed through rigorous clinical trials.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4015e2333>Concluding remarks</h2><p class="" id=d4015e2336>There are an extraordinary number of COVID-19 vaccines currently under development around the world. Highly optimistic timeframes of 12–18 months to get to the distribution of approved vaccines are being touted. Vaccines typically take many years or even decades to develop, e.g. the smallpox vaccine took 25 years to develop for human use, the HPV vaccine 15 years, the rotavirus vaccine 15 years, and the influenza vaccine 28 years. The COVID-19 vaccine initiatives aspire to have vaccines ready for distribution by 2021. This is a truly remarkable and unprecedented timeframe for vaccine development. The majority of vaccines won’t progress beyond pre-clinical or early clinical testing, but, of course, we need only one effective COVID-19 vaccine to halt this pandemic. Fewer than 10% of drugs or vaccines that enter clinical trials ever progress to become available for human use. For example, 30% fail at phase I trials. Of those that progress to phase II, 69% fail and then a further 42% fail at phase III. Of those products that successfully pass through phase III trials, a further 15% do not gain regulatory approval. Because of the drastically shorter time being allotted for the pre-clinical development of COVID-19 vaccine candidates, it is conceivable that a higher proportion of these candidates may fail during clinical testing. In addition to vaccine development, a number of resource-intensive activities will need to be undertaken in parallel, particularly the construction of manufacturing facilities capable of producing at a global scale. We are hopeful the unmatched resources being directed into the international vaccine R&amp;D effort will lead to a successful vaccine capable of stopping this new pandemic.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d4015e2343 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class=faculty-opinion-icon></span><span class="prime-red big">Faculty Opinions recommended</span></span><h2 class=main-title id=d4286>References</h2><div class="section ref-list"><a name=d4015e2343 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737216219"><span class="faculty-opinion-icon small"></span></a><a name=d4015e2350 class=n-a></a>Hui DS, Azhar EI, Madani TA, <i> et al.</i>: The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. <i>Int J Infect Dis.</i> 2020; <b>91</b>: 264–6. <a target=xrefwindow id=d4015e2361 href="http://www.ncbi.nlm.nih.gov/pubmed/31953166">PubMed Abstract </a> | <a target=xrefwindow id=d4015e2364 href="https://doi.org/10.1016/j.ijid.2020.01.009">Publisher Full Text </a> | <a target=xrefwindow id=d4015e2368 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7128332 ">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737216219">Faculty Opinions Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d4015e2381 class=n-a></a>Coronavirus disease (COVID-2019) situation reports. WHO. 2020. <a target=xrefwindow id=d4015e2383 href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports">Reference Source</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d4015e2392 class=n-a></a>WHO Director-General's opening remarks at the media briefing on COVID-19 - 13 March 2020. WHO. 2020. <a target=xrefwindow id=d4015e2394 href="https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-mission-briefing-on-covid-19---13-march-2020">Reference Source</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d4015e2403 class=n-a></a>Cohen J: With record-setting speed, vaccinemakers take their first shots at the new coronavirus. <i>Science.</i> 2020. <a target=xrefwindow id=d4015e2408 href="https://www.sciencemag.org/news/2020/03/record-setting-speed-vaccine-makers-take-their-first-shots-new-coronavirus">Reference Source</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d4015e2417 class=n-a></a>Draft landscape of Covid-19 candidate vaccines. World Health Organization. 2020; [cited 2020 6 July]. <a target=xrefwindow id=d4015e2419 href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines">Reference Source</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d4015e2429 class=n-a></a>NIH:Clinical Trials. 2020. <a target=xrefwindow id=d4015e2431 href="https://www.nih.gov/research-training/clinical-trials">Reference Source</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737705278"><span class="faculty-opinion-icon small"></span></a><a name=d4015e2440 class=n-a></a>Le TT, Andreadakis Z, Kumar A, <i> et al.</i>: The COVID-19 vaccine development landscape. <i>Nat Rev Drug Discov.</i> 2020; <b>19</b>(5): 305–6. <a target=xrefwindow id=d4015e2451 href="http://www.ncbi.nlm.nih.gov/pubmed/32273591">PubMed Abstract </a> | <a target=xrefwindow id=d4015e2454 href="https://doi.org/10.1038/d41573-020-00073-5">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737705278">Faculty Opinions Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d4015e2467 class=n-a></a>Williams J: Vector Design for Improved DNA Vaccine Efficacy, Safety and Production. <i>Vaccines (Basel).</i> 2013; <b>1</b>(3): 225–49. <a target=xrefwindow id=d4015e2475 href="http://www.ncbi.nlm.nih.gov/pubmed/26344110">PubMed Abstract </a> | <a target=xrefwindow id=d4015e2478 href="https://doi.org/10.3390/vaccines1030225">Publisher Full Text </a> | <a target=xrefwindow id=d4015e2481 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4494225">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d4015e2490 class=n-a></a>Bahl K, Senn JJ, Yuzhakov O, <i> et al.</i>: Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. <i>Mol Ther.</i> 2017; <b>25</b>(6): 1316–27. <a target=xrefwindow id=d4015e2501 href="http://www.ncbi.nlm.nih.gov/pubmed/28457665">PubMed Abstract </a> | <a target=xrefwindow id=d4015e2504 href="https://doi.org/10.1016/j.ymthe.2017.03.035">Publisher Full Text </a> | <a target=xrefwindow id=d4015e2508 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5475249">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d4015e2517 class=n-a></a>Geall AJ, Verma A, Otten GR, <i> et al.</i>: Nonviral delivery of self-amplifying RNA vaccines. <i>Proc Natl Acad Sci U S A.</i> 2012; <b>109</b>(36): 14604–9. <a target=xrefwindow id=d4015e2528 href="http://www.ncbi.nlm.nih.gov/pubmed/22908294">PubMed Abstract </a> | <a target=xrefwindow id=d4015e2531 href="https://doi.org/10.1073/pnas.1209367109">Publisher Full Text </a> | <a target=xrefwindow id=d4015e2535 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3437863">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/727261558"><span class="faculty-opinion-icon small"></span></a><a name=d4015e2544 class=n-a></a>Pardi N, Hogan MJ, Pelc RS, <i> et al.</i>: Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. <i>Nature.</i> 2017; <b>543</b>(7644): 248–51. <a target=xrefwindow id=d4015e2555 href="http://www.ncbi.nlm.nih.gov/pubmed/28151488">PubMed Abstract </a> | <a target=xrefwindow id=d4015e2558 href="https://doi.org/10.1038/nature21428">Publisher Full Text </a> | <a target=xrefwindow id=d4015e2562 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5344708">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/727261558">Faculty Opinions Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/735561875"><span class="faculty-opinion-icon small"></span></a><a name=d4015e2576 class=n-a></a>Zhang C, Maruggi G, Shan H, <i> et al.</i>: Advances in mRNA Vaccines for Infectious Diseases. <i>Front Immunol.</i> 2019; <b>10</b>: 594. <a target=xrefwindow id=d4015e2587 href="http://www.ncbi.nlm.nih.gov/pubmed/30972078">PubMed Abstract </a> | <a target=xrefwindow id=d4015e2590 href="https://doi.org/10.3389/fimmu.2019.00594">Publisher Full Text </a> | <a target=xrefwindow id=d4015e2594 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6446947">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/735561875">Faculty Opinions Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734452974"><span class="faculty-opinion-icon small"></span></a><a name=d4015e2607 class=n-a></a>Hobernik D, Bros M: DNA Vaccines-How Far From Clinical Use? <i>Int J Mol Sci.</i> 2018; <b>19</b>(11): 3605. <a target=xrefwindow id=d4015e2615 href="http://www.ncbi.nlm.nih.gov/pubmed/30445702">PubMed Abstract </a> | <a target=xrefwindow id=d4015e2618 href="https://doi.org/10.3390/ijms19113605">Publisher Full Text </a> | <a target=xrefwindow id=d4015e2621 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6274812">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734452974">Faculty Opinions Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d4015e2634 class=n-a></a>Inovio Inovio Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today. 2020. <a target=xrefwindow id=d4015e2636 href="https://www.prnewswire.com/news-releases/inovio-initiates-phase-1-clinical-trial-of-its-covid-19-vaccine-and-plans-first-dose-today-301035633.html">Reference Source</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d4015e2645 class=n-a></a>Inovio IVI, INOVIO, and KNIH to Partner with CEPI in Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine in South Korea. 2020. <a target=xrefwindow id=d4015e2647 href="https://www.ivi.int/ivi-inovio-and-knih-to-partner-with-cepi-in-a-phase-i-ii-clinical-trial-of-inovios-covid-19-dna-vaccine-in-south-korea/">Reference Source</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d4015e2656 class=n-a></a>Moderna Moderna Announces Award from U.S. Government Agency BARDA for up to $483 Million to Accelerate Development of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus. 2020. <a target=xrefwindow id=d4015e2658 href="https://pipelinereview.com/index.php/2020041774358/Vaccines/Moderna-Announces-Award-from-U.S.-Government-Agency-BARDA-for-up-to-$483-Million-to-Accelerate-Development-of-mRNA-Vaccine-mRNA-1273-Against-Novel-Coronavirus.html">Reference Source</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/738321500"><span class="faculty-opinion-icon small"></span></a><a name=d4015e2667 class=n-a></a>Jackson LA, Anderson EJ, Rouphael NG, <i> et al.</i>: An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. <i>N Engl J Med.</i> 2020. <a target=xrefwindow id=d4015e2675 href="http://www.ncbi.nlm.nih.gov/pubmed/32663912">PubMed Abstract </a> | <a target=xrefwindow id=d4015e2678 href="https://doi.org/10.1056/NEJMoa2022483">Publisher Full Text </a> | <a target=xrefwindow id=d4015e2681 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7377258">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/738321500">Faculty Opinions Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d4015e2695 class=n-a></a>Moderna Moderna Advances Late-Stage Development of its Vaccine (mRNA-1273) Against COVID-19. 2020. <a target=xrefwindow id=d4015e2697 href="https://www.businesswire.com/news/home/20200611005456/en/Moderna-Advances-Late-Stage-Development-Vaccine-mRNA-1273-COVID-19">Reference Source</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d4015e2706 class=n-a></a>Gaspar HB, Parsley KL, Howe S, <i> et al.</i>: Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. <i>Lancet.</i> 2004; <b>364</b>(9452): 2181–7. <a target=xrefwindow id=d4015e2717 href="http://www.ncbi.nlm.nih.gov/pubmed/15610804">PubMed Abstract </a> | <a target=xrefwindow id=d4015e2720 href="https://doi.org/10.1016/S0140-6736(04)17590-9">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d4015e2729 class=n-a></a>Ura T, Okuda K, Shimada M: Developments in Viral Vector-Based Vaccines. <i>Vaccines (Basel).</i> 2014; <b>2</b>(3): 624–41. <a target=xrefwindow id=d4015e2737 href="http://www.ncbi.nlm.nih.gov/pubmed/26344749">PubMed Abstract </a> | <a target=xrefwindow id=d4015e2740 href="https://doi.org/ 10.3390/vaccines2030624">Publisher Full Text </a> | <a target=xrefwindow id=d4015e2743 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4494222">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d4015e2752 class=n-a></a>Callaway E: The race for coronavirus vaccines: A graphical guide. <i>Nature.</i> 2020; <b>580</b>(7805): 576–577. <a target=xrefwindow id=d4015e2760 href="http://www.ncbi.nlm.nih.gov/pubmed/32346146">PubMed Abstract </a> | <a target=xrefwindow id=d4015e2763 href="https://doi.org/10.1038/d41586-020-01221-y">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d4015e2772 class=n-a></a>Tlaxca JL, Ellis S, Remmele RL: Live attenuated and inactivated viral vaccine formulation and nasal delivery: Potential and challenges. <i>Adv Drug Deliv Rev.</i> 2015; <b>93</b>: 56–78. <a target=xrefwindow id=d4015e2780 href="http://www.ncbi.nlm.nih.gov/pubmed/25312673">PubMed Abstract </a> | <a target=xrefwindow id=d4015e2783 href="https://doi.org/10.1016/j.addr.2014.10.002">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/736042200"><span class="faculty-opinion-icon small"></span></a><a name=d4015e2792 class=n-a></a>Le Nouën C, Collins PL, Buchholz UJ: Attenuation of Human Respiratory Viruses by Synonymous Genome Recoding. <i>Front Immunol.</i> 2019; <b>10</b>: 1250. <a target=xrefwindow id=d4015e2800 href="http://www.ncbi.nlm.nih.gov/pubmed/31231383">PubMed Abstract </a> | <a target=xrefwindow id=d4015e2803 href="https://doi.org/10.3389/fimmu.2019.01250">Publisher Full Text </a> | <a target=xrefwindow id=d4015e2806 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6558635">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/736042200">Faculty Opinions Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737454503"><span class="faculty-opinion-icon small"></span></a><a name=d4015e2820 class=n-a></a>Mueller S, Stauft CB, Kalkeri R, <i> et al.</i>: A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates. <i>Vaccine.</i> 2020; <b>38</b>(14): 2943–8. <a target=xrefwindow id=d4015e2831 href="http://www.ncbi.nlm.nih.gov/pubmed/32107060">PubMed Abstract </a> | <a target=xrefwindow id=d4015e2834 href="https://doi.org/10.1016/j.vaccine.2020.02.056">Publisher Full Text </a> | <a target=xrefwindow id=d4015e2838 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7092643">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737454503">Faculty Opinions Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d4015e2851 class=n-a></a>Nogales A, Baker SF, Ortiz-Riano E, <i> et al.</i>: Influenza A Virus Attenuation by Codon Deoptimization of the NS Gene for Vaccine Development. <i>J Virol.</i> 2014; <b>88</b>(18): 10525–40. <a target=xrefwindow id=d4015e2862 href="http://www.ncbi.nlm.nih.gov/pubmed/24965472">PubMed Abstract </a> | <a target=xrefwindow id=d4015e2865 href="https://doi.org/10.1128/JVI.01565-14">Publisher Full Text </a> | <a target=xrefwindow id=d4015e2869 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4178899">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d4015e2878 class=n-a></a>Jang YH, Seong B-L: Principles underlying rational design of live attenuated influenza vaccines. <i>Clin Exp Vaccine Res.</i> 2012; <b>1</b>(1): 35–49. <a target=xrefwindow id=d4015e2886 href="http://www.ncbi.nlm.nih.gov/pubmed/23596576">PubMed Abstract </a> | <a target=xrefwindow id=d4015e2889 href="https://doi.org/10.7774/cevr.2012.1.1.35">Publisher Full Text </a> | <a target=xrefwindow id=d4015e2892 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3623510">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d4015e2901 class=n-a></a>Vaccines. WHO, 2020; 22 April 2020. <a target=xrefwindow id=d4015e2903 href="https://www.who.int/ith/vaccines/en/">Reference Source</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d4015e2912 class=n-a></a>Vaccines and Preventable Diseases. CDC. 2018; 22 April 2020. <a target=xrefwindow id=d4015e2914 href="https://www.cdc.gov/vaccines/vpd/vaccines-list.html">Reference Source</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737996406"><span class="faculty-opinion-icon small"></span></a><a name=d4015e2923 class=n-a></a>Zhu FC, Li YH, Guan XH, <i> et al.</i>: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. <i>Lancet.</i> 2020; <b>395</b>(10240): 1845–54. <a target=xrefwindow id=d4015e2934 href="http://www.ncbi.nlm.nih.gov/pubmed/32450106">PubMed Abstract </a> | <a target=xrefwindow id=d4015e2937 href="https://doi.org/10.1016/S0140-6736(20)31208-3">Publisher Full Text </a> | <a target=xrefwindow id=d4015e2941 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7255193">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737996406">Faculty Opinions Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d4015e2955 class=n-a></a>NIH A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) (CTII-nCoV). 2020. <a target=xrefwindow id=d4015e2957 href="https://www.clinicaltrials.gov/ct2/show/NCT04341389">Reference Source</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d4015e2966 class=n-a></a>van Doremalen N, Lambe T, Spencer A, <i> et al.</i>: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. <i>Nature.</i> 2020. <a target=xrefwindow id=d4015e2974 href="http://www.ncbi.nlm.nih.gov/pubmed/32731258">PubMed Abstract </a> | <a target=xrefwindow id=d4015e2977 href="https://doi.org/10.1038/s41586-020-2608-y">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d4015e2986 class=n-a></a>McNamara A: Oxford vaccine: trial on pigs ‘boosts coronavirus immune response’. 2020. <a target=xrefwindow id=d4015e2988 href="https://www.sciencefocus.com/news/oxford-vaccine-trial-on-pigs-boosts-coronavirus-immune-response/">Reference Source</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d4015e2997 class=n-a></a>Haseltine W: Did The Oxford Covid Vaccine Work In Monkeys? Not Really. 2020. <a target=xrefwindow id=d4015e2999 href="https://www.forbes.com/sites/williamhaseltine/2020/05/16/did-the-oxford-covid-vaccine-work-in-monkeys-not-really/#14f137193c71">Reference Source</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d4015e3008 class=n-a></a>Kemp A: AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit. 2020. <a target=xrefwindow id=d4015e3010 href="https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-supply-europe-with-up-to-400-million-doses-of-oxford-universitys-vaccine-at-no-profit.html#:~:text=capacity%20to%20provide%20broad%20and,by%20the%20end%20of%202020">Reference Source</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d4015e3019 class=n-a></a>Laguipo A: Oxford COVID-19 vaccine trials move to stage 3 human trials. 2020. <a target=xrefwindow id=d4015e3021 href="https://www.news-medical.net/news/20200705/Oxford-COVID-19-vaccine-trials-move-to-stage-3-human-trials.aspx">Reference Source</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d4015e3031 class=n-a></a>Schmitz U, Lou L, Roberts C, <i> et al.</i>: 7.13 - Ribonucleic Acid Viruses: Antivirals for Influenza A and B, Hepatitis C Virus, and Respiratory Syncytial Virus. In: <i>Comprehensive Medicinal Chemistry II</i>. Taylor JB and Triggle DJ, Editors. Elsevier: Oxford. 2017; 373–417. <a target=xrefwindow id=d4015e3039 href="https://doi.org/10.1016/B0-08-045044-X/00214-5">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d4015e3048 class=n-a></a>Delrue I, Verzele D, Madder A, <i> et al.</i>: Inactivated virus vaccines from chemistry to prophylaxis: Merits, risks and challenges. <i>Expert Rev Vaccines.</i> 2012; <b>11</b>(6): 695–719. <a target=xrefwindow id=d4015e3059 href="http://www.ncbi.nlm.nih.gov/pubmed/22873127">PubMed Abstract </a> | <a target=xrefwindow id=d4015e3062 href="https://doi.org/10.1586/erv.12.38">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d4015e3071 class=n-a></a>Hampton LM, Farrell M, Ramirez-Gonzalez A, <i> et al.</i>: Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016. <i>MMWR Morb Mortal Wkly Rep.</i> 2016; <b>65</b>(35): 934–8. <a target=xrefwindow id=d4015e3082 href="http://www.ncbi.nlm.nih.gov/pubmed/27606675">PubMed Abstract </a> | <a target=xrefwindow id=d4015e3085 href="https://doi.org/10.15585/mmwr.mm6535a3">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d4015e3094 class=n-a></a>Gao Q, Bao L, Mao H, <i> et al.</i>: Rapid development of an inactivated vaccine for SARS-CoV-2. <i>bioRxiv.</i> 2020; 2020.04.17.046375. <a target=xrefwindow id=d4015e3102 href="https://doi.org/10.1101/2020.04.17.046375">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d4015e3111 class=n-a></a>Barrett PN, Mundt W, Kistner O, <i> et al.</i>: Vero cell platform in vaccine production: Moving towards cell culture-based viral vaccines. <i>Expert Rev Vaccines.</i> 2009; <b>8</b>(5): 607–18. <a target=xrefwindow id=d4015e3122 href="http://www.ncbi.nlm.nih.gov/pubmed/19397417">PubMed Abstract </a> | <a target=xrefwindow id=d4015e3125 href="https://doi.org/10.1586/erv.09.19">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d4015e3134 class=n-a></a>Josefsberg JO, Buckland B: Vaccine process technology. <i>Biotechnol Bioeng.</i> 2012; <b>109</b>(6): 1443–60. <a target=xrefwindow id=d4015e3142 href="http://www.ncbi.nlm.nih.gov/pubmed/22407777">PubMed Abstract </a> | <a target=xrefwindow id=d4015e3145 href="https://doi.org/10.1002/bit.24493">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d4015e3155 class=n-a></a>Tulloch F, Atkinson NJ, Evans DJ, <i> et al.</i>: RNA virus attenuation by codon pair deoptimisation is an artefact of increases in CpG/UpA dinucleotide frequencies. <i>Elife.</i> 2014; <b>3</b>: e04531. <a target=xrefwindow id=d4015e3166 href="http://www.ncbi.nlm.nih.gov/pubmed/25490153">PubMed Abstract </a> | <a target=xrefwindow id=d4015e3169 href="https://doi.org/10.7554/eLife.04531">Publisher Full Text </a> | <a target=xrefwindow id=d4015e3173 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4383024">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d4015e3182 class=n-a></a>First Ebola vaccine approved. <i>Nat Biotechnol.</i> 2020; <b>38</b>(1): 6. <a target=xrefwindow id=d4015e3190 href="http://www.ncbi.nlm.nih.gov/pubmed/31919440">PubMed Abstract </a> | <a target=xrefwindow id=d4015e3193 href="https://doi.org/10.1038/s41587-019-0385-7">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d4015e3202 class=n-a></a>Marshall D: Griffith University researchers on the road to COVID-19 vaccine. 2020. <a target=xrefwindow id=d4015e3204 href="https://news.griffith.edu.au/2020/04/23/griffith-university-researchers-on-the-road-to-covid-19-vaccine/">Reference Source</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d4015e3213 class=n-a></a>Vartak A, Sucheck SJ: Recent Advances in Subunit Vaccine Carriers. <i>Vaccines (Basel).</i> 2016; <b>4</b>(2): 12. <a target=xrefwindow id=d4015e3221 href="http://www.ncbi.nlm.nih.gov/pubmed/27104575">PubMed Abstract </a> | <a target=xrefwindow id=d4015e3224 href="https://doi.org/10.3390/vaccines4020012">Publisher Full Text </a> | <a target=xrefwindow id=d4015e3227 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4931629">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d4015e3236 class=n-a></a>WHO: MODULE 2: Types of Vaccine and Adverse Reactions. 2020. <a target=xrefwindow id=d4015e3238 href="https://vaccine-safety-training.org/types-of-vaccine.html">Reference Source</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/735983543"><span class="faculty-opinion-icon small"></span></a><a name=d4015e3247 class=n-a></a>Tai W, Chen J, Zhao G, <i> et al.</i>: Rational Design of Zika Virus Subunit Vaccine with Enhanced Efficacy. <i>J Virol.</i> 2019; <b>93</b>(17): e02187-18. <a target=xrefwindow id=d4015e3258 href="http://www.ncbi.nlm.nih.gov/pubmed/31189716">PubMed Abstract </a> | <a target=xrefwindow id=d4015e3261 href="https://doi.org/10.1128/JVI.02187-18">Publisher Full Text </a> | <a target=xrefwindow id=d4015e3265 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6694833">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/735983543">Faculty Opinions Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/732528637"><span class="faculty-opinion-icon small"></span></a><a name=d4015e3279 class=n-a></a>Pandey RK, Bhatt TK, Prajapati VK: Novel Immunoinformatics Approaches to Design Multi-epitope Subunit Vaccine for Malaria by Investigating Anopheles Salivary Protein. <i>Sci Rep.</i> 2018; <b>8</b>(1): 1125. <a target=xrefwindow id=d4015e3287 href="http://www.ncbi.nlm.nih.gov/pubmed/29348555">PubMed Abstract </a> | <a target=xrefwindow id=d4015e3290 href="https://doi.org/10.1038/s41598-018-19456-1">Publisher Full Text </a> | <a target=xrefwindow id=d4015e3293 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5773588">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/732528637">Faculty Opinions Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d4015e3306 class=n-a></a>Kelly DF, Moxon ER, Pollard AJ: <i>Haemophilus influenzae</i> type b conjugate vaccines. <i>Immunology.</i> 2004; <b>113</b>(2): 163–74. <a target=xrefwindow id=d4015e3317 href="http://www.ncbi.nlm.nih.gov/pubmed/15379976">PubMed Abstract </a> | <a target=xrefwindow id=d4015e3320 href="https://doi.org/10.1111/j.1365-2567.2004.01971.x ">Publisher Full Text </a> | <a target=xrefwindow id=d4015e3324 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1782565">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d4015e3333 class=n-a></a>Degos F: [Protein subunit vaccines: example of vaccination against hepatitis B virus]. <i>Rev Prat.</i> 1995; <b>45</b>(12): 1488–91. <a target=xrefwindow id=d4015e3341 href="http://www.ncbi.nlm.nih.gov/pubmed/7660001">PubMed Abstract </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d4015e3350 class=n-a></a>ExpreS2ion announces EU grant award for the COVID-19 vaccine development programme. 2020. <a target=xrefwindow id=d4015e3352 href="https://www.reuters.com/article/brief-expres2ion-announces-eu-grant-awar/brief-expres2ion-announces-eu-grant-award-for-the-covid-19-vaccine-development-programme-idUSFWN2AZ09R">Reference Source</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/733205843"><span class="faculty-opinion-icon small"></span></a><a name=d4015e3361 class=n-a></a>Khandia R, Munjal A, Dhama K, <i> et al.</i>: Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. <i>Front Immunol.</i> 2018; <b>9</b>: 597. <a target=xrefwindow id=d4015e3372 href="http://www.ncbi.nlm.nih.gov/pubmed/29740424">PubMed Abstract </a> | <a target=xrefwindow id=d4015e3375 href="https://doi.org/10.3389/fimmu.2018.00597">Publisher Full Text </a> | <a target=xrefwindow id=d4015e3379 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5925603">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/733205843">Faculty Opinions Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737076453"><span class="faculty-opinion-icon small"></span></a><a name=d4015e3392 class=n-a></a>Wan Y, Shang J, Sun S, <i> et al.</i>: Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. <i>J Virol.</i> 2020; <b>94</b>(5): e02015-19. <a target=xrefwindow id=d4015e3403 href="http://www.ncbi.nlm.nih.gov/pubmed/31826992">PubMed Abstract </a> | <a target=xrefwindow id=d4015e3406 href="https://doi.org/10.1128/JVI.02015-19">Publisher Full Text </a> | <a target=xrefwindow id=d4015e3410 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7022351">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737076453">Faculty Opinions Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737790348"><span class="faculty-opinion-icon small"></span></a><a name=d4015e3424 class=n-a></a>Iwasaki A, Yang Y: The potential danger of suboptimal antibody responses in COVID-19. <i>Nat Rev Immunol.</i> 2020; <b>20</b>(6): 339–41. <a target=xrefwindow id=d4015e3432 href="http://www.ncbi.nlm.nih.gov/pubmed/32317716">PubMed Abstract </a> | <a target=xrefwindow id=d4015e3435 href="https://doi.org/10.1038/s41577-020-0321-6">Publisher Full Text </a> | <a target=xrefwindow id=d4015e3438 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7187142">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737790348">Faculty Opinions Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 17 Aug 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-991/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-991/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University (Gold Coast Campus), Queensland, Australia<br/> <p> <div class=margin-bottom> Wern Hann Ng <br/> <span>Roles: </span> Conceptualization, Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Xiang Liu <br/> <span>Roles: </span> Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Suresh Mahalingam <br/> <span>Roles: </span> Conceptualization, Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-991/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 17 Aug 2020, 9:991 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.25998.1">https://doi.org/10.12688/f1000research.25998.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Ng WH <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=28692 data-id=25998 data-downloads="" data-views="" data-scholar="10.12688/f1000research.25998.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-991/v1/pdf?article_uuid=7818e880-4060-4a38-83c1-19244e92957b" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.25998.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Ng WH, Liu X and Mahalingam S. Development of vaccines for SARS-CoV-2 [version 1; peer review: 2 approved] <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):991 (<a href="https://doi.org/10.12688/f1000research.25998.1" target=_blank>https://doi.org/10.12688/f1000research.25998.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=25998 id=mobile-track-article-signin-25998 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/25998?target=/articles/9-991/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=28692 /> <input name=articleId type=hidden value=25998 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Shinji Makino</strong>, Department of Microbiology and Immunology, Institute for Human Infection and Immunity, University of Texas Medical Branch, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Gavin Koh</strong>, Diseases of the Developing World, GlaxoSmithKline, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 17 Aug 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-991/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-991/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=73977-69046></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=73976-69047></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/9-991/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>17 Aug 20</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Shinji Makino</strong>, Department of Microbiology and Immunology, Institute for Human Infection and Immunity, University of Texas Medical Branch, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Gavin Koh</strong>, Diseases of the Developing World, GlaxoSmithKline, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-991/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-991/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Development of vaccines for SARS-CoV-2".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-991/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-991/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-991/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Ng WH et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-991/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-991",
            templates : {
                twitter : "Development of vaccines for SARS-CoV-2. Ng WH et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-991/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Development of vaccines for SARS-CoV-2", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Development of vaccines for SARS-CoV-2", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/25998/28692")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "28692");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "69047": 1,
                           "69046": 2,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "fc26e7af-5593-44e1-b4dd-bc68857b4616";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-991.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-991.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-991.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-991.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-991.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>